Genzyme in Europe: The Moment of Truth
Executive Summary
Genzyme has long had a presence in Europe, but it now faces its most public challenges. With Fabrazyme having to share its orphan drug exclusivity, and sales of key growth-driver Renagel below expectations, the US firm is finding that although experience helps, it doesn't guarantee a leading market share.
You may also be interested in...
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
What Next In Oncology?
Oncology dominates pharma sales and pipeline league tables. But where is the next Keytruda?